- Tytuł:
- Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
- Autorzy:
- Źródło:
- In European Journal of Cancer September 2023 190
Czasopismo naukowe